Giant Cell Arteritis
6
Pipeline Programs
5
Companies
3
Clinical Trials
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
2
1
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
2100%
+ 3 programs with unclassified modality
On Market (1)
Approved therapies currently available
Competitive Landscape
4 companies ranked by most advanced pipeline stage
CP
Chugai PharmaJapan - Tokyo
2 programs1
1
TocilizumabPhase 3Monoclonal Antibody1 trial
tocilizumab and IV steroids combinationPhase 21 trial
Active Trials
Kiniksa PharmaceuticalsMA - Lexington
1 program1
mavrilimumabPhase 2Monoclonal Antibody1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Chugai PharmaTocilizumab
Chugai Pharmatocilizumab and IV steroids combination
Kiniksa Pharmaceuticalsmavrilimumab
Clinical Trials (3)
Total enrollment: 194 patients across 3 trials
Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement
Start: Sep 2021Est. completion: Aug 202566 patients
Phase 3Active Not Recruiting
Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA
Start: Sep 2020Est. completion: Dec 202258 patients
Phase 2Unknown
KPL-301 for Subjects With Giant Cell Arteritis
Start: Sep 2018Est. completion: Nov 202070 patients
Phase 2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
5 companies competing in this space